文献速递眼底病与葡萄膜炎

多中心评估循环生物标志物检测威胁视力的糖尿病视网膜病变

Multicenter Evaluation of Diagnostic Circulating Biomarkers to Detect Sight-Threatening Diabetic Retinopathy.
PubMed 文献 · JAMA Ophthalmol · 2022-01-01

这项多中心横断面研究纳入538名40岁及以上成人,分为无糖尿病史、2型糖尿病≥5年无糖尿病视网膜病变、非增殖性糖尿病视网膜病变伴糖尿病黄斑水肿、增殖性糖尿病视网膜病变四组,检测13种既往验证的生物标志物。在年龄、病程、族裔和糖化血红蛋白基础上加入胱抑素C后,对无糖尿病视网膜病变与威胁视力的糖尿病视网膜病变的区分能力在英国接近可接受(AUC 0.779),在印度为AUC 0.696。作者认为血清胱抑素C可能作为优先安排视网膜筛查的检测。

要点

  • 研究纳入538名参与者,英国274人、印度264人,分四组比较无糖尿病视网膜病变与威胁视力的糖尿病视网膜病变。
  • 在年龄、病程、族裔和糖化血红蛋白基础上加入胱抑素C,英国完全数据215人AUC 0.779(95%CI 0.700-0.857)。
  • 印度完全数据208人AUC 0.696(95%CI 0.602-0.791),作者认为胱抑素C可能用于优先安排视网膜筛查。

核心结论

  • 作者认为血清胱抑素C在英国和印度均具有较好的区分能力,循环胱抑素C水平可考虑作为识别需优先进行威胁视力的糖尿病视网膜病变视网膜筛查者的检测。

研究设计与样本

  • 多中心横断面研究,2018年10月22日至2021年12月31日收集数据,在英国3家门诊眼科诊所和印度2家中心平行开展。
  • 纳入40岁及以上成人,分为无糖尿病史、2型糖尿病至少5年且无糖尿病视网膜病变证据、非增殖性糖尿病视网膜病变伴糖尿病黄斑水肿、增殖性糖尿病视网膜病变4组,威胁视力的糖尿病视网膜病变包括后两组。
  • 采用酶联免疫吸附试验检测13种既往验证的生物标志物,以眼底照相和光学相干断层扫描诊断糖尿病视网膜病变严重程度和糖尿病黄斑水肿。

主要发现

  • 共纳入538名参与者,平均(标准差)年龄60.8(9.8)岁,男性319人(59.3%)。
  • 印度264人(49.1%),其中1组54人(20.5%)、2组53人(20.1%)、3组52人(19.7%)、4组105人(39.8%)。
  • 英国274人(50.9%),其中1组50人(18.2%)、2组70人(25.5%)、3组55人(20.1%)、4组99人(36.1%)。
  • 受试者工作特征曲线分析(无糖尿病视网膜病变对威胁视力的糖尿病视网膜病变)显示,在年龄、病程、族裔(英国)和糖化血红蛋白基础上加入胱抑素C后,英国完全数据215人AUC 0.779(95%CI 0.700-0.857),印度完全数据208人AUC 0.696(95%CI 0.602-0.791)。

关键数值与推荐

  • 在年龄、病程、族裔(英国)和糖化血红蛋白基础上加入胱抑素C后,英国完全数据215人AUC 0.779(95%CI 0.700-0.857)。
  • 在年龄、病程、族裔(英国)和糖化血红蛋白基础上加入胱抑素C后,印度完全数据208人AUC 0.696(95%CI 0.602-0.791)。

临床怎么用

  • 作者认为循环胱抑素C水平可考虑作为识别需优先进行威胁视力的糖尿病视网膜病变视网膜筛查者的检测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It is a global challenge to provide regular retinal screening for all people with diabetes to detect sight-threatening diabetic retinopathy (STDR). OBJECTIVE: To determine if circulating biomarkers could be used to prioritize people with type 2 diabetes for retinal screening to detect STDR. DESIGN, SETTING, AND PARTICIPANTS: This cross-sectional study collected data from October 22, 2018, to December 31, 2021. All laboratory staff were masked to the clinical diagnosis, assigned a study cohort, and provided with the database containing the clinical data. This was a multicenter study conducted in parallel in 3 outpatient ophthalmology clinics in the UK and 2 centers in India. Adults 40 years and older were categorized into 4 groups: (1) no history of diabetes, (2) type 2 diabetes of at least 5 years' duration with no evidence of DR, (3) nonproliferative DR with diabetic macular edema (DME), or (4) proliferative DR. STDR comprised groups 3 and 4. EXPOSURES: Thirteen previously verified biomarkers were measured using enzyme-linked immunosorbent assay. MAIN OUTCOMES AND MEASURES: Severity of DR and presence of DME were diagnosed using fundus photographs and optical coherence tomography. Weighted logistic regression and receiver operating characteristic curve analysis (ROC) were performed to identify biomarkers that discriminate STDR from no DR beyond the standard clinical parameters of age, disease duration, ethnicity (in the UK) and hemoglobin A1c. RESULTS: A total of 538 participants (mean [SD] age, 60.8 [9.8] years; 319 men [59.3%]) were recruited into the study. A total of 264 participants (49.1%) were from India (group 1, 54 [20.5%]; group 2, 53 [20.1%]; group 3, 52 [19.7%]; group 4, 105 [39.8%]), and 274 participants (50.9%) were from the UK (group 1, 50 [18.2%]; group 2, 70 [25.5%]; group 3, 55 [20.1%]; group 4, 99 [36.1%]). ROC analysis (no DR vs STDR) showed that in addition to age, disease duration, ethnicity (in the UK) and hemoglobin A1c, inclusion of cystatin C had near-acceptable discrimination power in both countries (area under the receiver operating characteristic curve [AUC], 0.779; 95% CI, 0.700-0.857 in 215 patients in the UK with complete data; AUC, 0.696; 95% CI, 0.602-0.791 in 208 patients in India with complete data). CONCLUSIONS AND RELEVANCE: Results of this cross-sectional study suggest that serum cystatin C had good discrimination power in the UK and India. Circulating cystatin-C levels may be considered as a test to identify those who require prioritization for retinal screening for STDR.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Gurudas S, Frudd K, Maheshwari JJ, et al. Multicenter Evaluation of Diagnostic Circulating Biomarkers to Detect Sight-Threatening Diabetic Retinopathy. JAMA Ophthalmol. 2022. PMID: 35511139. doi:10.1001/jamaophthalmol.2022.1175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。